GLP-1 Drugs Cut Breast Cancer Risk 30%, Slow Progression in 6 Tumor Types
Updated
Updated · Forbes · Jun 13
GLP-1 Drugs Cut Breast Cancer Risk 30%, Slow Progression in 6 Tumor Types
3 articles · Updated · Forbes · Jun 13
Summary
More than 200,000 mammograms in an observational study linked GLP-1 use to a 30% lower breast cancer risk among women aged 45 to 80.
Over 10,000 early-stage cancer patients in a separate study also showed slower disease progression across six tumor types, including colon, breast, liver and lung cancer.
Lung cancer data illustrated the gap: progression to stage IV was 22.3% without a GLP-1 drug versus 10% with one.
Obesity is tied to at least 13 cancers and affects about 2 in 5 U.S. adults, raising the prospect that GLP-1s could become a broader cancer-prevention tool.
The evidence remains preliminary because the studies were observational; randomized trials are still needed to prove causation and define which cancers, drugs and treatment durations matter most.
Beyond weight loss, do these popular drugs possess direct cancer-fighting abilities?
The cancer link is promising, but what are the hidden long-term risks?
GLP-1 Drugs Linked to 30% Lower Breast Cancer Incidence: ASCO 2026 Findings and Future Directions
Overview
The 2026 ASCO Annual Meeting highlighted exciting new research showing that GLP-1 receptor agonists, drugs originally used for diabetes and obesity, may help reduce cancer risk and improve outcomes. Experts are increasingly interested in how metabolic health affects cancer, especially since obesity is a known risk factor for many cancers. Recent studies presented at the meeting found that GLP-1 drugs are linked to lower rates of breast cancer and may slow cancer progression. These findings have sparked a new wave of research, suggesting GLP-1 drugs could offer a novel approach to cancer prevention and treatment.